JMP Securities lowered the firm’s price target on Hookipa Pharma (HOOK) to $7 from $24 and keeps an Outperform rating on the shares. Hookipa announced Wednesday that it will reduce its workforce by about 80% starting this quarter and pause the eseba-vec cancer vaccine program in HPV16+ head-and-neck cancer, including an early termination of the Phase 1/2, not due to efficacy or safety, looking instead to partner the program, the analyst tells investors in a research note. The firm has removed eseba-vec from its valuation.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HOOK:
- Hookipa Pharma announces workforce reduction of 80%, pause of eseba-vec program
- Hookipa Pharma price target lowered to $48 from $50 at RBC Capital
- Hookipa Pharma Reports Q3 Earnings Amid Strategic Changes
- Closing Bell Movers: Applied Materials down 6% after earnings, guidance
- Hookipa Pharma reports Q3 EPS ($1.10), consensus ($1.90)